ENAGenomicsZhejiang Shaoxing Topgen Biomedical Technology Co., LTD.https://www.ebi.ac.uk/ena/browser/view/PRJNA1077640Next generation sequencing (NGS) was performed on the tumor DNA of a lung adenocarcinoma patient, revealing a fusion between VIT exon 2 and ALK exon 20 with a variant frequency of 10.32%. After one year of therapy, the patient remained in a stable disease state. However, the patient experienced a relapse and underwent a second NGS test. The results showed a fusion of exon 2 of VIT with exon 20 of ALK, with a variant frequency of 13.13%. Ultimately, the patient achieved a progression free survival of 16 months.ENAnon-small cell lung cancer, non-small cell cancer of the lung, non-small cell carcinoma of lung, NSCLC, Client., Patient, non-small cell lung carcinoma, Clients, NSCLC - non-small cell lung cancer, patient, Non-small cell lung cancer, non-small cell cancer of lung, non-small cell carcinoma of the lung, non-small cell lung carcinoma (disease)falseNext generation sequecing data of a NSCLC patient2024-05-112024-05-11PRJNA1077640